Geron (NASDAQ:GERN) Price Target Raised to $6.00 at Needham & Company LLC

Geron (NASDAQ:GERNFree Report) had its price target increased by Needham & Company LLC from $5.00 to $6.00 in a research note issued to investors on Friday, Benzinga reports. They currently have a buy rating on the biopharmaceutical company’s stock.

A number of other research analysts have also issued reports on the stock. Wedbush reissued an outperform rating and set a $7.00 target price on shares of Geron in a research note on Friday. The Goldman Sachs Group boosted their price objective on Geron from $4.00 to $5.00 and gave the stock a buy rating in a research report on Friday, March 15th. TD Cowen began coverage on Geron in a research report on Monday, April 29th. They issued a buy rating and a $10.00 target price on the stock. Finally, Robert W. Baird lowered Geron from an outperform rating to a neutral rating and set a $4.50 price target for the company. in a research report on Tuesday, April 30th. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. Based on data from MarketBeat, Geron presently has a consensus rating of Moderate Buy and an average price target of $6.50.

Read Our Latest Research Report on GERN

Geron Trading Up 18.0 %

Shares of NASDAQ GERN opened at $4.59 on Friday. Geron has a 12-month low of $1.64 and a 12-month high of $5.15. The company has a market cap of $2.72 billion, a price-to-earnings ratio of -13.11 and a beta of 0.43. The company has a current ratio of 3.67, a quick ratio of 3.67 and a debt-to-equity ratio of 0.03. The stock’s 50 day simple moving average is $3.65 and its 200 day simple moving average is $2.69.

Geron (NASDAQ:GERNGet Free Report) last issued its earnings results on Thursday, May 2nd. The biopharmaceutical company reported ($0.09) earnings per share for the quarter, topping the consensus estimate of ($0.10) by $0.01. Geron had a negative return on equity of 68.16% and a negative net margin of 38,730.00%. The firm had revenue of $0.30 million for the quarter, compared to analyst estimates of $0.15 million. Equities research analysts expect that Geron will post -0.35 EPS for the current year.

Insider Transactions at Geron

In related news, CEO John A. Scarlett sold 600,000 shares of the business’s stock in a transaction that occurred on Tuesday, June 4th. The stock was sold at an average price of $4.00, for a total transaction of $2,400,000.00. Following the sale, the chief executive officer now owns 600,000 shares of the company’s stock, valued at $2,400,000. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Company insiders own 3.10% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. Vishria Bird Financial Group LLC lifted its holdings in Geron by 17.7% in the 1st quarter. Vishria Bird Financial Group LLC now owns 24,265 shares of the biopharmaceutical company’s stock valued at $80,000 after acquiring an additional 3,650 shares during the last quarter. Moody National Bank Trust Division raised its holdings in shares of Geron by 4.0% in the 4th quarter. Moody National Bank Trust Division now owns 132,053 shares of the biopharmaceutical company’s stock worth $279,000 after purchasing an additional 5,079 shares in the last quarter. Amalgamated Bank lifted its stake in Geron by 9.0% during the third quarter. Amalgamated Bank now owns 69,122 shares of the biopharmaceutical company’s stock valued at $147,000 after purchasing an additional 5,681 shares during the last quarter. CANADA LIFE ASSURANCE Co boosted its holdings in Geron by 12.3% during the first quarter. CANADA LIFE ASSURANCE Co now owns 64,438 shares of the biopharmaceutical company’s stock worth $212,000 after buying an additional 7,034 shares in the last quarter. Finally, Crewe Advisors LLC increased its holdings in shares of Geron by 870.0% in the first quarter. Crewe Advisors LLC now owns 9,700 shares of the biopharmaceutical company’s stock valued at $32,000 after buying an additional 8,700 shares in the last quarter. Institutional investors own 73.71% of the company’s stock.

Geron Company Profile

(Get Free Report)

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis.

Read More

Analyst Recommendations for Geron (NASDAQ:GERN)

Receive News & Ratings for Geron Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Geron and related companies with MarketBeat.com's FREE daily email newsletter.